QNTM (Quantum BioPharma Ltd.) Net Profit

Corporate emblem and logo of quantumbiopharma.com (QNTM)

The lack of recurring revenue and dependence on external capital create a high debt load for Quantum BioPharma Ltd (QNTM). The company's net income trend clearly confirms this deficit, where -0.03 expresses the current value of the metric. Stability is provided by the defensive qualities of the biotech sector, which remains independent of crises, while growth potential is driven by unique patents for treating rare skin pathologies based on cannabinoids.

QNTM (Quantum BioPharma) Company Net Income history from 08/16/2024 to 10/29/2026

Financial and market metric breakdowns for Quantum BioPharma (QNTM)

- price and consensus price forecast:
Stock Quotes Quantum BioPharma Corp|QNTM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Quantum BioPharma Corp|QNTM - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Quantum BioPharma|QNTM - Company Book Value|Market-to-Book Ratio quantumbiopharma.com|QNTM - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Quantum BioPharma Ltd|QNTM - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Quantum BioPharma Ltd.|QNTM - Company Aggregate Debts|Debts to Book Value Quantum BioPharma Corp|QNTM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Quantum BioPharma|Critical Liquidity quantumbiopharma.com
- net income and valuation multiples indicators:
QNTM - Net Income
Fundamental valuation:QNTM Quantum BioPharma Corp
Flagship merchandise of Quantum BioPharma Ltd.

A comparative asset analysis requires an evaluation of daily net profit, which, at the value of -0.03, reflects the business's real-time reaction to market changes without quarterly lags. This financial performance metric for Quantum BioPharma Ltd (QNTM) captures actual cash flow, accounting for the company's expenditures on standard environmental oversight and laboratory safety, allowing investors to identify the risk of share devaluation in a timely manner.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Annual Net Income Aquestive Therapeutics Inc|SCPH: Net Income|TECX - Net Profit|TNXP: Net Profit|China SXT Pharmaceuticals, Inc. (SXTC) - Net Profit|Company Net Income Eupraxia Pharmaceuticals, Inc.|Company Profit BHST (BioHarvest Sciences, Inc.)|Net Income EXOZ (Invizyne Technologies, Inc.)|Profit After Payment of Taxes ORMP|Entera Bio - Net Income|Net Profit ipatherapeutics.com HYFT|ABVC - Company Net Income|Cumberland Pharmaceuticals Inc (CPIX) - Net Income|FGEN (FibroGen Corp) - Net Income|Telomir Pharmaceuticals Corp - Final Profit|RANI (Rani Therapeutics Holdings) - Net Profit|Company Net Income SNYR|Net Profit RLYB|Net Financial Result lexariabioscience.com|Company Net Income Pulmatrix Corp PULM|Pheton Holdings Limited (PTHL) - Company Net Income|APM - Company Net Income|Profit After Tax LYRA|IBO: Net Profit|TNF Pharmaceuticals, Inc. - Final Profit|YCBD (cbdMD Inc.) - Net Profit|Net Profit PainReform Corp|Company Net Income Altamira Therapeutics (CYTO)|LIPO (lipella.com) - Final Profit|Company Net Income OptiNose OPTN|PIRS - Net Income|Procaps Group SA - Net Profit|PTPI - Net Profit|QLI (Qilian International) - Net Income|acelyrin.com - Final Profit|Company Net Income TFF Pharmaceuticals, Inc.